ATP6V0E1 Activators
ATP6V0E1 activators encompass a broad spectrum of chemicals that indirectly enhance the function of the ATP6V0E1 subunit of the V-ATPase proton pump, essential for acidifying intracellular compartments. The mechanism of activation is often a secondary cellular response to an initial inhibition or disruption of proton gradients across membranes. For instance, some chemicals in this class directly inhibit the V-ATPase. This inhibition, especially at suboptimal concentrations or upon subsequent exposure, can lead to a compensatory cellular response that upregulates the expression or assembly of V-ATPase components to restore pH balance. This response includes an increase in the activity of the ATP6V0E1 subunit. Similarly, chemicals like Amiloride and Niclosamide, by disrupting sodium or proton gradients, respectively, invoke a compensatory increase in V-ATPase activity as the cell attempts to maintain ionic and pH homeostasis.
The chemical-induced upregulation of ATP6V0E1 involves not only the expression level of the protein but also its incorporation into functional proton pumps. Calcium-modulating agents like Esculetin and Verapamil indirectly influence V-ATPase activity by affecting the assembly of the V0 and V1 domains, a process sensitive to intracellular calcium levels. Ionophores and uncouplers such as Monensin and FCCP disturb ionic balances, eliciting a response wherein ATP6V0E1 activity is heightened to compensate for altered membrane potential and proton gradients. These activators do not bind directly to ATP6V0E1 but instead create a cellular milieu that necessitates enhanced proton pump activity, wherein ATP6V0E1 plays a pivotal role. The upregulation of ATP6V0E1, therefore, is a reflection of the cell's effort to maintain homeostasis in the face of chemical challenges that initially disrupt proton pump function, ionic balances, or both. The activity of ATP6V0E1 is critical for maintaining the functional integrity of cellular processes such as endosomal sorting, nutrient processing, and receptor-mediated endocytosis, as well as for the overall cellular bioenergetics and metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Esculetin | 305-01-1 | sc-200486 sc-200486A | 1 g 5 g | $44.00 $212.00 | 7 | |
Esculetin affects calcium homeostasis, which can influence V-ATPase activity since intracellular calcium levels modulate the assembly and disassembly of the V0 and V1 domains of the pump. Elevated calcium may enhance the assembly of V-ATPases, thus increasing ATP6V0E1 activity indirectly. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
This antihelminthic drug alters intracellular pH by uncoupling the proton gradient. Cells may respond by upregulating V-ATPase activity, including ATP6V0E1, to compensate for the pH imbalance, thus promoting the acidification of organelles and maintaining cellular functions. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
By modulating sodium and hydrogen exchange across membranes, Amiloride can indirectly affect the proton gradient, which might lead to increased V-ATPase activity, including the ATP6V0E1 component, in an attempt to maintain acid-base balance within the cell. | ||||||
Pyr3 | 1160514-60-2 | sc-301624 sc-301624A sc-301624B | 5 mg 10 mg 25 mg | $151.00 $260.00 $520.00 | ||
As an inhibitor of TRPC3 channels that mediate calcium entry, Pyr3 can affect calcium signaling, thereby potentially altering the regulation of V-ATPase assembly. This may enhance the trafficking and activity of ATP6V0E1-containing proton pumps to cellular compartments requiring acidification. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
This compound is known to disrupt membrane potential and may affect V-ATPase activity by altering ionic balances across cellular membranes. As a response, cells may increase ATP6V0E1 activity to counterbalance changes and maintain ionic and pH homeostasis. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
As a calcium channel blocker, Verapamil can influence the intracellular calcium concentration, which is a known regulator of V-ATPase assembly. This can indirectly lead to increased activity of ATP6V0E1 in the V-ATPase complex as the cell attempts to maintain calcium homeostasis. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin, a sodium ionophore, disrupts ionic gradients across membranes. This can lead to a compensatory upregulation of V-ATPases, including ATP6V0E1, to restore ionic balance and pH levels within intracellular compartments, especially within lysosomes and endosomes. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
This compound inhibits mitochondrial ATP synthase, leading to an increase in proton gradient. To balance the disrupted proton gradient, the cell may enhance the activity of other proton pumps such as V-ATPases, potentially leading to increased recruitment or activity of ATP6V0E1. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $105.00 $214.00 $6255.00 | 2 | |
Affecting various cellular signaling pathways, Emodin can modulate intracellular pH levels. Cells might respond by upregulating ATP6V0E1-containing V-ATPase activity to maintain the required acidic environment within organelles, thus indirectly stimulating ATP6V0E1 activity. | ||||||